452 related articles for article (PubMed ID: 34418266)
21. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
[TBL] [Abstract][Full Text] [Related]
22. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
23. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
24. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
25. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
[TBL] [Abstract][Full Text] [Related]
26. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
27. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
28. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
[TBL] [Abstract][Full Text] [Related]
29. Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer.
Godbole N; Quinn A; Carrion F; Pelosi E; Salomon C
Semin Cancer Biol; 2023 Nov; 96():64-81. PubMed ID: 37820858
[TBL] [Abstract][Full Text] [Related]
30. Viral Vectors, Exosomes, and Vexosomes: Potential armamentarium for delivering CRISPR/Cas to cancer cells.
Farzanehpour M; Miri A; Alvanegh AG; Gouvarchinghaleh HE
Biochem Pharmacol; 2023 Jun; 212():115555. PubMed ID: 37075815
[TBL] [Abstract][Full Text] [Related]
31. Exosomes for CRISPR-Cas9 Delivery: The Cutting Edge in Genome Editing.
Aslan C; Zolbanin NM; Faraji F; Jafari R
Mol Biotechnol; 2023 Nov; ():. PubMed ID: 38012525
[TBL] [Abstract][Full Text] [Related]
32. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing.
Whitley JA; Cai H
J Extracell Vesicles; 2023 Sep; 12(9):e12343. PubMed ID: 37723839
[TBL] [Abstract][Full Text] [Related]
33. Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy.
Aziz A; Rehman U; Sheikh A; Abourehab MAS; Kesharwani P
J Biomater Sci Polym Ed; 2023 Feb; 34(3):398-418. PubMed ID: 36083788
[TBL] [Abstract][Full Text] [Related]
34. Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing.
Fang T; Cao X; Ibnat M; Chen G
J Nanobiotechnology; 2022 Aug; 20(1):354. PubMed ID: 35918694
[TBL] [Abstract][Full Text] [Related]
35. Nonviral Nanoparticles for CRISPR-Based Genome Editing: Is It Just a Simple Adaption of What Have Been Developed for Nucleic Acid Delivery?
Qiu M; Glass Z; Xu Q
Biomacromolecules; 2019 Sep; 20(9):3333-3339. PubMed ID: 31342740
[TBL] [Abstract][Full Text] [Related]
36. Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies.
Xu Q; Zhang Z; Zhao L; Qin Y; Cai H; Geng Z; Zhu X; Zhang W; Zhang Y; Tan J; Wang J; Zhou J
J Control Release; 2020 Oct; 326():455-467. PubMed ID: 32711027
[TBL] [Abstract][Full Text] [Related]
37. Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing.
Yao X; Lyu P; Yoo K; Yadav MK; Singh R; Atala A; Lu B
J Extracell Vesicles; 2021 Mar; 10(5):e12076. PubMed ID: 33747370
[TBL] [Abstract][Full Text] [Related]
38. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
39. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
[TBL] [Abstract][Full Text] [Related]
40. Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles.
Huang X; Li A; Xu P; Yu Y; Li S; Hu L; Feng S
J Nanobiotechnology; 2023 Jun; 21(1):184. PubMed ID: 37291577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
